VTAK
Catheter Precision, Inc.
Medical - Devices
Market Cap$1M
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
VTAK vs BSX vs MDT vs ATRC
Revenue, margins, valuation, and 5-year total return — side by side.
BSX
Boston Scientific Corporation
Medical - Devices
Market Cap$80.15B
5Y Perf.+42.0%
MDT
Medtronic plc
Medical - Devices
Market Cap$97.62B
5Y Perf.-22.8%
ATRC
AtriCure, Inc.
Medical - Instruments & Supplies
Market Cap$1.33B
5Y Perf.-45.0%
VTAK vs BSX vs MDT vs ATRC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VTAK | BSX | MDT | ATRC |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $1M | $80.15B | $97.62B | $1.33B |
| Revenue (TTM) | $730K | $20.07B | $35.48B | $552M |
| Net Income (TTM) | $-17M | $2.89B | $4.61B | $-5M |
| Gross Margin | 20.3% | 69.0% | 61.9% | 75.5% |
| Operating Margin | -19.6% | 19.8% | 17.9% | -0.4% |
| Forward P/E | — | 16.0x | 13.8x | 428.7x |
| Total Debt | $2M | $12.42B | $28.52B | $88M |
| Cash & Equiv. | $3M | $2.04B | $2.22B | $167M |
VTAK vs BSX vs MDT vs ATRC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VTAK
BSX
MDT
ATRC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Catheter Precision,… (VTAK) | 100 | 0.0 | -100.0% |
| Boston Scientific C… (BSX) | 100 | 142.0 | +42.0% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
| AtriCure, Inc. (ATRC) | 100 | 55.0 | -45.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VTAK vs BSX vs MDT vs ATRC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDT leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and dividend income and shareholder returns. Boston Scientific Corporation is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
VTAK
Catheter Precision, Inc.
The Specific-Use Pick
VTAK plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
BSX
Boston Scientific Corporation
The Growth Play
BSX is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
- 143.6% 10Y total return vs ATRC's 84.4%
- Lower volatility, beta 0.30, Low D/E 50.7%, current ratio 1.62x
- Beta 0.30, current ratio 1.62x
Best for: growth exposure and long-term compounding
MDT
Medtronic plc
The Income Pick
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Lower P/E (13.8x vs 428.7x)
- 3.7% yield; 36-year raise streak; the other 3 pay no meaningful dividend
- -5.5% vs VTAK's -83.2%
Best for: income & stability
ATRC
AtriCure, Inc.
The Secondary Option
ATRC lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BSX | 19.9% revenue growth vs VTAK's -5.0% |
| Value | MDT | Lower P/E (13.8x vs 428.7x) |
| Quality / Margins | BSX | 14.4% margin vs VTAK's -23.8% |
| Stability / Safety | BSX | Beta 0.30 vs VTAK's 1.07 |
| Dividends | MDT | 3.7% yield; 36-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | MDT | -5.5% vs VTAK's -83.2% |
| Efficiency (ROA) | MDT | 175.8% ROA vs VTAK's -68.2%, ROIC 6.0% vs -58.8% |
VTAK vs BSX vs MDT vs ATRC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2025
FY 2025
VTAK vs BSX vs MDT vs ATRC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBSXLAGGINGATRC
Who Leads Where
BSX leads in 3 of 6 categories
MDT leads 2 • VTAK leads 0 • ATRC leads 0 • 1 tied
Explore the data ↓ATRCAtriCure, Inc.
0leads
VTAKCatheter Precision, I…
0leads
MDTMedtronic plc
2leads
BSXBoston Scientific Cor…
3leads
6 Total Categories
CATEGORYLEADERvs MDTvs VTAKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BSX3/6
Valuation MetricsMultiples, price ratios, and targets
MDT3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BSX5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BSX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
MDT1/1
Income & Cash Flow (Last 12 Months)
BSX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 48608.2x VTAK's $730,000. BSX is the more profitable business, keeping 14.4% of every revenue dollar as net income compared to VTAK's -23.8%. On growth, VTAK holds the edge at +135.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $730,000 | $20.1B | $35.5B | $552M |
| EBITDAEarnings before interest/tax | -$12M | $4.7B | $9.4B | $13M |
| Net IncomeAfter-tax profit | -$17M | $2.9B | $4.6B | -$5M |
| Free Cash FlowCash after capex | -$10M | $3.6B | $5.4B | $54M |
| Gross MarginGross profit ÷ Revenue | +20.3% | +69.0% | +61.9% | +75.5% |
| Operating MarginEBIT ÷ Revenue | -19.6% | +19.8% | +17.9% | -0.4% |
| Net MarginNet income ÷ Revenue | -23.8% | +14.4% | +13.0% | -0.8% |
| FCF MarginFCF ÷ Revenue | -13.2% | +18.1% | +15.2% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +135.4% | +15.9% | +8.8% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.4% | +18.5% | -11.9% | +101.6% |
BSX leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
MDT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 24% valuation discount to BSX's 27.8x P/E. On an enterprise value basis, MDT's 14.1x EV/EBITDA is more attractive than ATRC's 73.2x.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $1M | $80.1B | $97.6B | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $282,262 | $90.5B | $123.9B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.12x | 27.80x | 21.09x | -109.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.96x | 13.80x | 428.71x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 35.17x | — |
| EV / EBITDAEnterprise value multiple | — | 24.25x | 14.06x | 73.24x |
| Price / SalesMarket cap ÷ Revenue | 3.26x | 3.99x | 2.91x | 2.49x |
| Price / BookPrice ÷ Book value/share | 0.23x | 3.29x | 2.04x | 2.55x |
| Price / FCFMarket cap ÷ FCF | — | 21.91x | 18.83x | 27.56x |
MDT leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
BSX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
BSX delivers a 12.4% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-3 for VTAK. VTAK carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), BSX scores 7/9 vs VTAK's 4/9, reflecting strong financial health.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.7% | +12.4% | +9.4% | -1.0% |
| ROA (TTM)Return on assets | -68.2% | +6.9% | +175.8% | -0.7% |
| ROICReturn on invested capital | -58.8% | +8.8% | +6.0% | -0.6% |
| ROCEReturn on capital employed | -41.7% | +11.1% | +7.5% | -0.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.15x | 0.51x | 0.59x | 0.18x |
| Net DebtTotal debt minus cash | -$1M | $10.4B | $26.3B | -$79M |
| Cash & Equiv.Liquid assets | $3M | $2.0B | $2.2B | $167M |
| Total DebtShort + long-term debt | $2M | $12.4B | $28.5B | $88M |
| Interest CoverageEBIT ÷ Interest expense | -62.72x | 11.03x | 9.08x | 0.47x |
BSX leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BSX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BSX five years ago would be worth $12,469 today (with dividends reinvested), compared to $0 for VTAK. Over the past 12 months, MDT leads with a -5.5% total return vs VTAK's -83.2%. The 3-year compound annual growth rate (CAGR) favors BSX at 0.5% vs VTAK's -84.9% — a key indicator of consistent wealth creation.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -58.7% | -43.1% | -20.0% | -33.1% |
| 1-Year ReturnPast 12 months | -83.2% | -47.8% | -5.5% | -15.7% |
| 3-Year ReturnCumulative with dividends | -99.7% | +1.5% | -6.3% | -45.0% |
| 5-Year ReturnCumulative with dividends | -100.0% | +24.7% | -29.2% | -64.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | +143.6% | +24.3% | +84.4% |
| CAGR (3Y)Annualised 3-year return | -84.9% | +0.5% | -2.1% | -18.1% |
BSX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BSX and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSX is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than VTAK's 1.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MDT currently trades 71.6% from its 52-week high vs VTAK's 5.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.07x | 0.30x | 0.42x | 0.95x |
| 52-Week HighHighest price in past year | $15.68 | $109.50 | $106.33 | $43.18 |
| 52-Week LowLowest price in past year | $0.79 | $53.64 | $75.91 | $26.10 |
| % of 52W HighCurrent price vs 52-week peak | +5.3% | +49.3% | +71.6% | +60.9% |
| RSI (14)Momentum oscillator 0–100 | 37.6 | 35.4 | 29.2 | 44.0 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 15.6M | 7.9M | 678K |
Evenly matched — BSX and MDT each lead in 1 of 2 comparable metrics.
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: BSX as "Buy", MDT as "Buy", ATRC as "Buy". Consensus price targets imply 95.3% upside for ATRC (target: $51) vs 43.8% for MDT (target: $110). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.
| Metric | VTAKCatheter Precisio… | BSXBoston Scientific… | MDTMedtronic plc | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $91.33 | $109.50 | $51.33 |
| # AnalystsCovering analysts | — | 43 | 49 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.7% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 36 | — |
| Dividend / ShareAnnual DPS | — | — | $2.78 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.3% | +0.8% |
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway
BSX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
Best OverallBoston Scientific Corporati… (BSX)Leads 3 of 6 categories
Loading custom metrics...
VTAK vs BSX vs MDT vs ATRC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VTAK or BSX or MDT or ATRC a better buy right now?
For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.
9% revenue growth year-over-year, versus -5. 0% for Catheter Precision, Inc. (VTAK). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Boston Scientific Corporation (BSX) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VTAK or BSX or MDT or ATRC?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Boston Scientific Corporation at 27. 8x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x.
03Which is the better long-term investment — VTAK or BSX or MDT or ATRC?
Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +24.
7%, compared to -100. 0% for Catheter Precision, Inc. (VTAK). Over 10 years, the gap is even starker: BSX returned +143. 6% versus VTAK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VTAK or BSX or MDT or ATRC?
By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.
30β versus Catheter Precision, Inc. 's 1. 07β — meaning VTAK is approximately 257% more volatile than BSX relative to the S&P 500. On balance sheet safety, Catheter Precision, Inc. (VTAK) carries a lower debt/equity ratio of 15% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — VTAK or BSX or MDT or ATRC?
By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.
9% versus -5. 0% for Catheter Precision, Inc. (VTAK). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to 30. 8% for Medtronic plc. Over a 3-year CAGR, VTAK leads at 167. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VTAK or BSX or MDT or ATRC?
Boston Scientific Corporation (BSX) is the more profitable company, earning 14.
4% net margin versus -39. 6% for Catheter Precision, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -26. 8% for VTAK. At the gross margin level — before operating expenses — VTAK leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VTAK or BSX or MDT or ATRC more undervalued right now?
On forward earnings alone, Medtronic plc (MDT) trades at 13.
8x forward P/E versus 428. 7x for AtriCure, Inc. — 414. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.
08Which pays a better dividend — VTAK or BSX or MDT or ATRC?
In this comparison, MDT (3.
7% yield) pays a dividend. VTAK, BSX, ATRC do not pay a meaningful dividend and should not be held primarily for income.
09Is VTAK or BSX or MDT or ATRC better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, VTAK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VTAK and BSX and MDT and ATRC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VTAK is a small-cap quality compounder stock; BSX is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; ATRC is a small-cap quality compounder stock. MDT pays a dividend while VTAK, BSX, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(VTAK: 135.4% · BSX: 15.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.